Media - Sonova News Room
AB announces FDA approval of two new sound processors
Stäfa (Switzerland), 18 August 2015 – Sonova Holding AG, the world’s leading provider of hearing solutions, announces today that its subsidiary Advanced Bionics (AB) has received FDA (Food and Drug Administration) approval in the United States for its new Naída CI Q90 and Q30 sound processors. FDA approval follows Health Canada approval earlier this year. Distribution of the Naída CI Q90 sound processor is expected later this year in the United States and Canada. The Naída CI Q30 is designed to meet the needs of the global market and will be available in specific markets outside of North America.
Commenting on the approval, Lukas Braunschweiler, CEO of Sonova said: “Building on the unique innovations introduced with the Naída CI Q70 sound processor in 2013, the new Naída CI Q90 and Q30 processors are further evidence of our clear commitment to be customer driven, bringing together the innovation DNA of AB and Phonak. The new devices deliver on our promise to innovate, differentiate and provide our customers with the most comprehensive range of products in the industry. I am confident that this launch will further support the long-term, sustainable growth of Sonova’s implant business.”
The Q Series gives cochlear implant recipients access to the innovative combined technologies of AB and Phonak. Phonak Binaural VoiceStream Technology gives the Naída CI processors the unique ability to work together for improved hearing in challenging situations. These extraordinary binaural benefits that this technology provides for effortless communication are unique in the industry.
The new Q90 is the top-of-the-line processor in the Naída CI Q Series from Advanced Bionics, following the previous release of the Q70. Offering new PowerCel innovations that reduce size and improve battery life as well as new microphone technology for focusing on speech, the Naída CI Q90 now raises the bar as the premium choice for recipients who want the full line of features in the most compact package. Some of the advanced Q Series features include industry leading automation with new innovations that block obtrusive sounds, such as wind and echoes, to improve hearing in challenging settings. Supporting the Naída CI Q Series, the latest version of AB’s signature fitting software, SoundWave 2.3, also received FDA approval.
For more information please visit www.advancedbionics.com
– End –